7DZX

Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 8D2

Summary for 7DZX

• Entry DOI: 10.2210/pdb7dzx/pdb
• EMDB information: 30918
• Descriptor: Spike glycoprotein, Fab Heavy chain of enhancing antibody, Fab light chain of enhancing antibody (3 entities in total)
• Functional Keywords: sars-cov2, spike protein, fab, enhancing antibody, viral protein
• Biological source: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2); More
• Total number of polymer chains: 5
• Total formula weight: 462487.46

Authors

Liu, Y.,Soh, W.T.,Li, S.,Kishikawa, J.,Hirose, M.,Kato, T.,Standley, D.,Okada, M.,Arase, H. (deposition date: 2021-01-26, release date: 2021-06-02, Last modification date: 2024-03-27)

Primary citation

Liu, Y.,Soh, W.T.,Kishikawa, J.I.,Hirose, M.,Nakayama, E.E.,Li, S.,Sasai, M.,Suzuki, T.,Tada, A.,Arakawa, A.,Matsuoka, S.,Akamatsu, K.,Matsuda, M.,Ono, C.,Torii, S.,Kishida, K.,Jin, H.,Nakai, W.,Arase, N.,Nakagawa, A.,Matsumoto, M.,Nakazaki, Y.,Shindo, Y.,Kohyama, M.,Tomii, K.,Ohmura, K.,Ohshima, S.,Okamoto, T.,Yamamoto, M.,Nakagami, H.,Matsuura, Y.,Nakagawa, A.,Kato, T.,Okada, M.,Standley, D.M.,Shioda, T.,Arase, H.
An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies.
Cell, 184:3452-3466.e18, 2021

PubMed Abstract: Antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein prevent SARS-CoV-2 infection. However, the effects of antibodies against other spike protein domains are largely unknown. Here, we screened a series of anti-spike monoclonal antibodies from coronavirus disease 2019 (COVID-19) patients and found that some of antibodies against the N-terminal domain (NTD) induced the open conformation of RBD and thus enhanced the binding capacity of the spike protein to ACE2 and infectivity of SARS-CoV-2. Mutational analysis revealed that all of the infectivity-enhancing antibodies recognized a specific site on the NTD. Structural analysis demonstrated that all infectivity-enhancing antibodies bound to NTD in a similar manner. The antibodies against this infectivity-enhancing site were detected at high levels in severe patients. Moreover, we identified antibodies against the infectivity-enhancing site in uninfected donors, albeit at a lower frequency. These findings demonstrate that not only neutralizing antibodies but also enhancing antibodies are produced during SARS-CoV-2 infection.

PubMed: 34139176
DOI: 10.1016/j.cell.2021.05.032

Experimental method

ELECTRON MICROSCOPY (3.53 Å)